For almost 35 years, Genentech has been dedicated to rigorous and groundbreaking science, balancing basic biomedical discovery and translational research to develop therapies for unmet medical needs. Today, the Genentech Research and Early Development (gRED) organization focuses its efforts on basic and applied science in the areas of oncology, immunology, neuroscience and infectious disease.
gRED aspires to make fundamental scientific discoveries and to develop these discoveries into first- and best-in-class therapeutics that provide unique benefits to patients. To reach these goals, we actively encourage creativity and initiative among our researchers and welcome the diverse set of skills and backgrounds each brings to the gRED team. For example, many scientists pursue projects of individual interest in addition to helping Genentech meet its goals.
All research takes place in South San Francisco, Calif., where gRED houses the largest single-site biotech research facility in the world and functions as an independent research organization within the Roche Group. The scientists who work here consistently publish important papers in peer-reviewed journals and earn national recognition for their work — three of our researchers are members of the National Academy of Sciences. Employees often say that gRED combines the best of the corporate and academic worlds, allowing researchers not only to conduct high-quality science with esteemed colleagues but also to watch an idea move from the laboratory into development and out to a patient in a clinic.